The DOI matches its Crossref record; 142 of the 143 references it cites were found in a registry or an index; 63 of the 190 sources its claims cite were checked for support.
Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms
Open accessAbstract
BACKGROUND: The prevalence of autism spectrum disorder (ASD) has surged, with an estimated 1 in 36 eight-year-olds in the United States meeting criteria for ASD in 2020. Autistic individuals face elevated rates of co-occurring medical, psychiatric, and behavioral conditions compared to non-autistic individuals. The rising ASD-patient demand is increasingly outpacing the capacity of ASD-specialty clinics, resulting in urgent need for autism-competent providers in general practice settings. This work aims to empower healthcare providers, especially primary care providers (PCPs), with guidelines for the recognition and safe pharmacologic management of common co-occurring psychiatric and behavioral conditions in ASD. METHODS: Lurie Center for Autism medical providers, who have extensive experience in ASD care, delineated approaches for recognition and pharmacological treatment of sleep disturbances, attention-deficit/hyperactivity disorder (ADHD), anxiety, depression, and irritability tailored to ASD patients. Pharmacological guidelines were iteratively refined until consensus was reached. Treatment differences relative to standard of care (SOC) of non-autistic individuals are noted. Key literature and clinical trial results were reviewed to supplement clinical experience. RESULTS: -adrenergic agonists are more suitable than stimulants for some ASD-ADHD patients, buspirone and mirtazapine are preferred to selective serotonin reuptake inhibitors (SSRIs) for anxiety, and duloxetine, mirtazapine, bupropion, and vortioxetine are recommended ahead of SSRIs for depression. Addressing irritability in ASD requires interdisciplinary evaluation of contributing factors, and guanfacine, risperidone, or aripiprazole may be appropriate, depending on severity. CONCLUSIONS: Recognition and treatment of co-occurring psychiatric and behavioral conditions in autistic patients must account for differences in clinical presentation and medication effectiveness and tolerability. Drawing on evidence-based clinical insights, these guidelines seek to support PCPs in making informed decisions when prescribing medications for ASD patients with co-occurring psychiatric and behavioral conditions, ultimately enhancing access to timely, comprehensive care for all individuals with ASD.
Overview
CoChat Summary
## TL;DR
This paper is an expert-consensus proposal for ASD-specific prescribing guidance for five common co-occurring symptom domains: sleep disturbances, ADHD, anxiety, depression, and irritability. It argues that medication choices, dosing, and monitoring in autism often differ from non-autistic standard of care and are especially relevant for primary care providers.
## Key findings
- The authors state that in ASD, first-line approaches for sleep disturbance still align with non-autistic care: sleep hygiene and melatonin; they report melatonin had an average overall improvement rate of over 84% across 18 studies and recommend 1–3 mg about 30 min before sleep, titrating up to 10 mg.
- For ADHD in ASD, they report a 4-week crossover RCT of methylphenidate in 72 children aged 5–14 years where 35/72 (49%) were responders, but 18% discontinued due to adverse events; they also report an 8-week RCT of guanfacine ER in 62 children aged 5–14 years where ABC-Hyperactivity fell 43.6% vs 13.2% on placebo and response was 50% vs 9.4%.
- For anxiety in ASD, they cite a 10-week RCT of mirtazapine in 30 youth aged 5–17 years: 47% on mirtazapine were “much improved” or “very much improved” vs 20% on placebo, with a non-significant PARS trend (effect size 0.63); they recommend buspirone and mirtazapine ahead of SSRIs.
- For depression in ASD, the paper reports there are no RCTs of antidepressant treatment specifically for depression in ASD, and recommends duloxetine, mirtazapine, bupropion, and vortioxetine ahead of SSRIs; for irritability, it notes guanfacine may be used first, with risperidone or aripiprazole for more severe cases.
## Methods
- Expert-consensus guideline development by clinicians and researchers from the Lurie Center for Autism, based on their clinical experience treating ASD across the lifespan.
- The team iteratively drafted pharmacologic pathways for sleep, ADHD, anxiety, depression, and irritability, then revised them through interviews, feedback, and cross-checking until consensus was reached.
- They supplemented clinical expertise with a targeted literature search using PubMed and Google Scholar, emphasizing seminal and recent studies and current recommendations.
## Limitations
- The paper explicitly says the guidance is based on consensus from a single site, with many prescribers sharing similar training or mentoring backgrounds, which limits the breadth of perspectives.
- The authors state their clinic is highly specialized, so their experience may be biased toward a particular patient population; they also note the manuscript focuses mainly on psychopharmacology and does not cover the full range of behavioral/therapeutic approaches or the needs of people with co-occurring genetic syndromes.
- Evident from the text: much of the evidence base is limited; the paper repeatedly notes few RCTs, no RCTs for several medications/indications in ASD, and a lack of validated diagnostic and outcome measures for co-occurring conditions in ASD.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
47 Valid · 6 Not valid · 86 Not checked · 38 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Since the long-term use of these medications in young children has yet to be studied, they are not recommended for long-term use for young children [67].”
§ Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms > Results and discussion > Sleep disturbances
What the sources say
- Disputedcites [67] Gober HJ, Li KH, Yan K, Bailey AJ, Carleton BC. Hydroxyzine use in preschool children and its effect on neurodevelopment: A population-based longitudinal study. Front Psychiatry. 2021;12:721875. sourceExperimental — accuracy not yet measured
The Introduction describes a prospective long-term safety study of cetirizine in children aged 1–2 years, with developmental outcomes assessed up to 18 months after treatment stopped. The paper also investigates repetitive hydroxyzine use in children under five. Thus, the blanket claim that long-term antihistamine use in young children has yet to be studied is contrary to this source, although the source says evidence for hydroxyzine specifically was limited. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Sleep disorders have been correlated with daytime sleepiness, cognitive, attentional, behavioral, and emotional challenges, as well as poorer health-related quality of life for children with ASD [12, 13, 46].”
§ Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms > Results and discussion > Sleep disturbances
What the sources say
- Not checked — no full text of the sourcecites [12] Limoges É, Bolduc C, Berthiaume C, Mottron L, Godbout R. Relationship between poor sleep and daytime cognitive performance in young adults with autism. Res Dev Disabil. 2013;34(4):1322–35. source
- Not checked — no full text of the sourcecites [13] Sadikova E, Dovgan K, Mazurek MO. Longitudinal examination of sleep problems and symptom severity in children with autism spectrum disorder. J Autism Dev Disord. 2023;53(4):1673–81. source
- Partly supportedcites [46] Fadini CC, Lamônica DA, Fett-Conte AC, Osório E, Zuculo GM, Giacheti CM, et al. Influence of sleep disorders on the behavior of individuals with autism spectrum disorder. Front Hum Neurosci. 2015;9(JUNE):347. sourceExperimental — accuracy not yet measured
The Introduction links sleep problems with attention deficits, anxiety, depression, and behavioral difficulties. The Discussion and Conclusions report correlations between sleep disorders and thought or behavioral problems in the ASD group, and document excessive daytime sleepiness. The paper does not report a correlation with poorer health-related quality of life. (LLM, conf=0.87)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Melatonin has been shown to reduce sleep latency (the amount of time it takes to fall asleep) [61].”
§ Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms > Results and discussion > Sleep disturbances
What the sources say
- Supportedcites [61] Malow B, Adkins KW, McGrew SG, Wang L, Goldman SE, Fawkes D, et al. Melatonin for sleep in children with autism: a controlled trial examining dose, tolerability, and outcomes. J Autism Dev Disord. 2012;42(8):1729–37 (author reply 1738). source
The Results (Actigraphy section; page not provided) report that sleep latency decreased significantly with melatonin treatment (p < 0.0001). The study concerned children with autism, which is the population in which this source directly demonstrates the claim. (LLM, conf=0.93)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A recent non-randomized, prospective observational cohort study evaluated 323 children with ADHD who were initiating pharmacotherapy and who also demonstrated either high or low ASD symptoms [82].”
§ Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms > Results and discussion > Attention-Deficit/Hyperactivity Disorder
What the sources say
- Supportedcites [82] Lilja MM, Sandblom E, Lichtenstein P, Serlachius E, Hellner C, Bhagia J, et al. The effect of autistic traits on response to and side-effects of pharmacological ADHD treatment in children with ADHD: results from a prospective clinical cohort. J Neurodev Disord. 2022;14(1):17. source
The Abstract’s Methods section identifies the study as a non-randomized, observational, prospective cohort. It reports 323 children aged 6–17 with ADHD who were starting pharmacological treatment, divided into groups with high or low levels of ASD symptoms. (LLM, conf=0.95)
plainn = 323- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“PedPRM has been shown to be efficacious and safe for the long-term treatment of insomnia in children with ASD in initial research [63].”
§ Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms > Results and discussion > Sleep disturbances
What the sources say
- Supportedcites [63] Maras A, Schroder CM, Malow BA, Findling RL, Breddy J, Nir T, et al. Long-term efficacy and safety of pediatric prolonged-release melatonin for insomnia in children with autism spectrum disorder. J Child Adolesc Psychopharmacol. 2018;28(10):699–710. source
The Conclusions state that PedPRM was a safe and effective long-term treatment for insomnia in children with ASD or neurogenetic disorders, with effects maintained through 52 weeks. The Discussion describes the one-year efficacy and safety findings; although the follow-up was open-label, the claim does not assert that long-term efficacy was established against placebo. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
73 more claims · 15 with their cited sources checked
Create a free account to see all 177 claims and to verify the 16 references still open.
- Probably not a substantial claim. 53
- It may state two separate claims as one. 67
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Diagnostic and Statistical Manual of Mental Disorders.
Widiger, T. A. (2000) · Encyclopedia of Psychology, Vol. 3. · doi:10.1037/10518-009 · Cited by 19,744
(1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.12.1073 · Cited by 3,372
Global prevalence of autism: A systematic review update
Zeidan, J., Fombonne, E., Scorah, J., Ibrahim, A., Durkin, M. S., Saxena, S., Yusuf, A., Shih, A., & Elsabbagh, M. (2022) · Autism Research · doi:10.1002/aur.2696 · Cited by 3,117 · cited 2×
“Current ASD prevalence estimates are now 1 in 36 for children in the U.S. [1] and in the last decade the global median prevalence of ASD children and adults is 10 per 1000 [3].”
Maenner, M. J., Warren, Z., Williams, A. R., Amoakohene, E., Bakian, A. V., Bilder, D. A., Durkin, M. S., Fitzgerald, R. T., Furnier, S. M., Hughes, M. M., et al. (2023) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7202a1 · Cited by 2,706 · cited 2×
“The escalating prevalence of autism spectrum disorder (ASD) in recent years [1–4] has created an urgent need for additional medical providers capable of delivering autism-competent care [5–7].”
Global Prevalence of Autism and Other Pervasive Developmental Disorders
Elsabbagh, M., Divan, G., Koh, Y., Kim, Y. S., Kauchali, S., Marcín, C., Montiel‐Nava, C., Patel, V., Paula, C. S., Wang, C., et al. (2012) · Autism Research · doi:10.1002/aur.239 · Cited by 2,636 · cited 1×
“1, 2, 3, 4 and 5 involve a degree of context-dependent decision making due to the limited knowledge base in the literature.”
Owens, J. A., Spirito, A., & McGuinn, M. (2000) · Sleep · doi:10.1093/sleep/23.8.1d · Cited by 2,535 · cited 1×
“…examiner can ask some key questions such as how long it takes to fall asleep, when the patient wakes up in the morning, when and how many times the patient wakes up during the night, how many hours the patient sleeps, is the patient well rested in the morning, and where does the patient sleep [49].”
Maenner, M. J., Shaw, K. A., Bakian, A. V., Bilder, D. A., Durkin, M. S., Esler, A., Furnier, S. M., Hallas, L., Hall-Lande, J., Hudson, A., et al. (2021) · MMWR. Surveillance Summaries · doi:10.15585/mmwr.ss7011a1 · Cited by 1,818
Risperidone in Children with Autism and Serious Behavioral Problems
McCracken, J. T., McGough, J., Shah, B., Cronin, P., Hong, D., Aman, M. G., Arnold, L. E., Lindsay, R., Nash, P., Hollway, J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa013171 · Cited by 1,574 · cited 3×
“Currently, only two drugs have been approved by the United States (U.S.) Food and Drug Administration (FDA) for use in the ASD population: risperidone [23] and aripiprazole [24].”
InfluentialSelf-citationAnxiety Disorders in Children and Adolescents with Autistic Spectrum Disorders: A Meta-Analysis
van Steensel, F. J. A., Bögels, S. M., & Perrin, S. (2011) · Clinical Child and Family Psychology Review · doi:10.1007/s10567-011-0097-0 · Cited by 1,463
Research works printed but not linked: 2
- American Psychiatric Association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision (DSM-5-TR®): Test questions for the diagnostic criteria. Muskin PR, Dickerman AL, Drysdale A, Holderness CC, editors. Arlington, TX: American Psychiatric Association Publishing; 2023. 1120 p.
- American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 4th Ed. Washington, DC; 1994.
Cited by
Sclabassi, E., Peret, S., Qian, C., & Gao, Y. (2025) · Biomedicines · doi:10.3390/biomedicines13123025 · Cited by 15
“Manter et al. proposed guideline-oriented recommendations for managing common co-occurring psychiatric symptoms in ASD, underscoring the importance of individualized treatment plans, therapeutic drug monitoring, and structured follow-up [96].”
Aljead, M., Qashta, A., Jalal, Z., & Jones, A. M. (2025) · Pharmaceuticals · doi:10.3390/ph18111644 · Cited by 13
“The most frequently prescribed SSRIs for these associated comorbidities include citalopram, fluoxetine, sertraline, and escitalopram [102].”
InfluentialHe, J., Lin, Z., Lin, X., Wang, C., Cao, M., Xia, R., & Hong, W. (2025) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2025.106162 · Cited by 7
Wang, Y., & Zhang, Y. (2025) · Neuropharmacology and Therapy · doi:10.15212/npt-2025-0008 · Cited by 10
“ASD comprises a group of neurodevelopmental conditions characterized by impairments in social communication and repetitive behaviors, with etiologies involving genetic factors, abnormal neurodevelopment, environmental influences, and imbalances in neurotransmitters [138].”
Applying biologically anchored subtypes to advance precision medicine in autism spectrum disorder
Choi, T.-Y., Gunawan, A., Seo, D., Park, J., Ahn, E. H., Suh, S. W., Fuccillo, M. V., & Choi, K. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.107219 · Cited by 5
Metadata
- Authors
- Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., Dakin, K., Hooker, J. M., & McDougle, C. J.
- Affiliations
- Massachusetts General Hospital (US)
- Harvard University (US)
- Beth Israel Deaconess Medical Center (US)
- Corresponding author
- McDougle, Christopher J.
- ORCID
- Venue
- BMC Medicine
- Published
- 2025-01-07
- Volume
- 23
- Issue
- 1
- Pages
- 11-11
- ISSN
- 1741-7015 (ISSN-L)
- PMC
- PMC11705908
- OpenAlex
- W4406116750
- Cited by
- 51
- References
- 143
- Citations by year
- 2026: 34 · 2025: 17
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc-nd
- creativecommons.org/licenses/by-nc-nd/4.0 (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0 (vor)
- Locations
- BMC Medicine (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cognitive Neuroscience › Autism Spectrum Disorder Research
- Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
- Health Sciences › Medicine › Psychiatry and Mental health › Child Nutrition and Feeding Issues
- Keywords
- autism spectrum disorder, pharmacotherapy, primary care, sleep disorders, attention deficit hyperactivity disorder, anxiety, depression, irritability, sympathomimetic drugs, buspirone, mirtazapine, duloxetine, guanfacine, risperidone, aripiprazole, drug tolerability
- MeSH terms
- Autism Spectrum Disorder, Anxiety, Attention Deficit Disorder with Hyperactivity, Depression, Humans, Sleep Wake Disorders, Comorbidity, Practice Guidelines as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms. https://app.cochat.ai/papers/10.1186/s12916-024-03814-0
- The paper
- Manter, M. A., Birtwell, K. B., Bath, J., Friedman, N. D. B., Keary, C. J., Neumeyer, A. M., Palumbo, M. L., Thom, R. P., Stonestreet, E., Brooks, H., Dakin, K., Hooker, J. M., & McDougle, C. J. (2025). Pharmacological treatment in autism: a proposal for guidelines on common co-occurring psychiatric symptoms. BMC Medicine. https://doi.org/10.1186/s12916-024-03814-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.